ArticleJournal of medical biochemistry2026
Investigate the effect of oxygen-driven salbutamol combined with methylprednisolone on bronchial asthma from the perspective of serum molecular markers.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study explores the application of oxygen-driven salbutamol (SA) combined with methylprednisolone (MP) in bronchial asthma (BA) from the perspective of objective clinical markers, including serum inflammatory response, oxidative stress response, immunoglobulin, and pulmonary ventilation function. Methods: A retrospective analysis was performed on 207 pediatric BA patients admitted to our hospital between January 2022 and January 2025. Of them, 114 children received MP combined with SA nebulization (control group), and 93 children received MP combined with oxygen-driven SA (observation group). The pulmonary ventilation function, inflammatory mediators (HIF-1a, IL-4, IL-6, IL-8 and TNF-a), stress response indicators (SOD, NO, ET-1 and MDA) and immunoglobulin (IgE, IgA, IgM and IgG) were detected and compared before and after treatment. Results: Post-treatment, the observation group demonstrated superior pulmonary ventilation function and significantly lower levels of inflammatory mediators (HIF-1a, IL-4, IL-6, IL-8, and TNF-a) compared to the control group (P < 0.05). Regarding stress response, the SOD level in the observation group was higher after treatment, while the levels of NO, ET-1, and MDA were lower (P < 0.05). In addition, IgE was lower and IgA was higher in the observation group than in the control group after treatment (P < 0.05). Conclusions: The combination of oxygen-driven SA and MP is more effective in mitigating inflammatory, stress responses and optimizing immune function in pediatric BA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.